INS and Hyperglycemia: STZ is a DNA alkylating agent administered via intraperitoneal route to destroy a high percentage of endogenous β-cells resulting in the reduction in endogenous insulin production, hyperglycemia, and glycosuria; nondiabetic control mice are treated with vehicle (0.1 M sodium citrate, pH 4.5) [13].